After strong Q3, no $55B deals in AbbVie’s future, CEO says. But a smaller one? Maybe

Carly Helfand No Shire? No problem for AbbVie. At least, for now. FiercePharma News

AstraZeneca finally bails on troubled Targacept after years of failure

Damian Garde After 9 years of fruitless work on treatments for Alzheimer's disease and depression, AstraZeneca is dissolving its partnership with Targacept, leaving the battered ...

Sunesis shares crushed in a rout after leukemia PhIII ends in defeat

John Carroll Shares of South San Francisco-based Sunesis were crushed this morning after the biotech put out word that its drug vosaroxin had flunked a Phase III test for acute myeloid ...

Ascension hospitals bar Genentech reps after cancer drug distribution switch

Tracy Staton One hospital chain has struck back at Roche's Genentech unit for switching its top 3 cancer treatments to specialty distributors. Ascension Health, a Roman Catholic-based ...

Sanofi and Regneron prep their cardio contender for FDA review after a Phase III sweep

Damian Garde Sanofi and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew Phase III trials in which the drug ...

Sarepta slips after new CSO is quickly pushed out

John Carroll So what happened to Sarepta's ($ SRPT) new chief scientific officer? Hired just 7 months ago, the biotech issued a one-liner in an 8-K this morning stating simply ...

New scrutiny for GlaxoSmithKline after news of 2001 bribery-related housecleaning in China

Carly Helfand GlaxoSmithKline's bribery woes in China apparently go back a bit further than the $ 489 million scandal that broke last summer. The U.K. company has acknowledged ...

Top officials at FDA’s India office bolt after less than a year

Eric Palmer FDA Commissioner Margaret Hamburg has urged India's drugmakers and regulators to get on board with international quality standards, while promising close cooperation ...

Sage soars after banking $90M in an up-sized IPO

Damian Garde Sage Therapeutics rocketed up more than 60% in its first day on Wall Street, bringing in $ 90 million to bankroll the company's CNS treatments and stirring hopes for ...

Bind shares slide after Amgen walks out of $180M collaboration deal

John Carroll Amgen has bowed out of a $ 180 million collaboration with Cambridge, MA-based Bind Therapeutics, ending work on a new therapy for solid tumors by amping up an Amgen drug ...

After multiple studies, MannKind finally wins an FDA OK for inhaled insulin Afrezza

John Carroll Three years and hundreds of millions of dollars after MannKind was handed its second FDA rejection on Afrezza, the third time proved the charm for the inhaled insulin. ...

Teva keeps the faith after another rebuke for Copaxone’s heir

Damian Garde Teva's $ 4-billion-a-year multiple sclerosis treatment Copaxone is slated to lose patent protection next year, and the Israeli drugmaker is struggling to move the ...
Page 4 of 13« First...23456...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS